|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tommorrow 2002: Pain
Datamonitor, May 2002
New markets for pipeline drugs will provide the largest growth opportunities across the spectrum of classes used to treat different pain types. For example, the successful uptake of Arcoxia in chronic low back pain will ensure that by 2009 it will be the best selling second-generation Cox-ii inhibitor on the market. Due to the strength and depth of competition in this lucrative market, the need to differentiate or exploit new areas is key to the uptake of all pipeline therapies. This report provides an in-depth analysis of the current pain pipeline. The report profiles drugs currently being developed for the treatment of pain, assessing their clinical trial data, marketing strength, patient potential, and opinion leader insight. The report also looks at the future development of the pain market in terms of forecast sales to 2009, patient potential, as well as future launches of key pipeline products. With a combined analysis of both the current and future markets, the report provides you with a holistic look at the potential of the current pain product pipeline as well as the threats and opportunities associated with this market.
Customers who bought this item also bought
Pain Drugs: Problems and Opportunities
Pain Therapeutics - Drugs, Markets and Companies
Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
The CNS Market Outlook to 2010
Injectable Generic Drugs: Prospects and Opportunities to 2010
Competitive Strategies in Pain Management, 2001 Edition
Market Dynamics: Pain - The Escalating Battle Between Merck and Pfizer
|
|
|
|
